11 terminated. 11 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Terminated 11 |
| Phase 1 | 1 | Terminated 1 |
Follow ixabepilone: new trials by email Literature Review of ixabepilone trials Research Report on ixabepilone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. Ixabepilone Injection - Metastatic Breast Cancer | Phase 2 | Terminated | Allarity Therapeutics | 13 | 2021-03-01 | 2026-03-12 |
| Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) ixabepilone, bevacizumab - Non-squamous Non-small Cell Lung Cancer | Phase 2 | Terminated | Providence Health & Services | 6 | 2010-02-01 | 2015-09-07 |
| Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer hydroxychloroquine, ixabepilone - Breast Cancer | Phase 1 / Phase 2 | Terminated | University of Medicine and Dentistry of New Jersey | 6 | 2009-02-01 | 2023-08-09 |
| Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT) ixabepilone - Metastatic Breast Cancer | Phase 2 | Terminated | Hellenic Cooperative Oncology Group | 64 | 2008-11-01 | 2011-05-18 |
| Ixabepilone to Treat Cervical Cancer Ixempra (Ixabepilone (BMS-247550) ) - Cervical Carcinoma, Cervical Adenocarcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 41 | 2008-11-01 | 2019-11-21 |
| A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer Ixabepilone - Prostatic Diseases, Genital Neoplasms, Male | Phase 2 | Terminated | Cedars-Sinai Medical Center | 11 | 2008-04-01 | 2018-10-24 |
| Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2, Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2, Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2 - Breast Neoplasms | Phase 2 | Terminated | R-Pharm | 62 | 2008-02-01 | 2016-03-10 |
| Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer trastuzumab, ixabepilone, laboratory biomarker analysis - HER2-positive Breast Cancer, Recurrent Breast Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 39 | 2004-01-01 | 2014-06-02 |
| BMS-247550 in Treating Patients With Metastatic Colorectal Cancer ixabepilone, Fluoropyrimidine, Irinotecan - Colorectal Cancer | Phase 2 | Terminated | University of Alabama at Birmingham | 2 | 2002-02-01 | 2013-08-05 |
| BMS-247550 in Treating Patients With Liver or Gallbladder Cancer ixabepilone, laboratory biomarker analysis - Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 50 | 2001-08-01 | 2014-05-14 |
| BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma ixabepilone - Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 26 | 2001-06-01 | 2015-04-15 |
Breast Neoplasms (5) · Adenocarcinoma (1) · Bile Duct Neoplasms (1) · Breast Neoplasms, Male (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Gallbladder Neoplasms (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Neoplasms, Glandular and Epithelial (1) · Prostatic Diseases (1) · Prostatic Neoplasms (1) · Rectal Neoplasms (1)
National Cancer Institute (NCI) (4) · Allarity Therapeutics (1) · Cedars-Sinai Medical Center (1) · Hellenic Cooperative Oncology Group (1) · Providence Health & Services (1) · R-Pharm (1) · University of Alabama at Birmingham (1) · University of Medicine and Dentistry of New Jersey (1)
United States (9) · Belgium (1) · Finland (1) · Germany (1) · Greece (1) · Italy (1) · Netherlands (1) · Poland (1) · United Kingdom (1)
Andres Forero-Torres, MD, CSU (1) · Antonio T Fojo, M.D. (1) · Craig Bunnell (1) · George Fountzilas (1) · Hedy Kindler (1) · Mitchell E Gross, MD, PhD (1) · Rachel Sanborn, MD (1) · Scott Okuno (1) · Vassil Karantza-Wadsworth, MD (1)
N01CM17104 (1), N01CM62201 (1), N01CM62206 (1), P30CA006516 (1), P30CA014599 (1), P30CA072720 (1)